13 research outputs found
Comparison of the rates of antibiotic changes after each test<sup>A</sup>.
<p>Comparison of the rates of antibiotic changes after each test<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181548#t001fn002" target="_blank"><sup>A</sup></a>.</p
Performance of Verigene BC-GP and BC-GN for bacteremia evaluation<sup>*</sup>.
<p>Performance of Verigene BC-GP and BC-GN for bacteremia evaluation<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181548#t002fn002" target="_blank">*</a></sup>.</p
Performance of Verigene BC-GP and BC-GN in multiple organism identification<sup>A</sup>.
<p>Performance of Verigene BC-GP and BC-GN in multiple organism identification<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181548#t003fn001" target="_blank"><sup>A</sup></a>.</p
Performance of Verigene BC-GP and BC-GN in resistance detection.
<p>Performance of Verigene BC-GP and BC-GN in resistance detection.</p
Additional file 1 of Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
Additional file 1. Supplemental Figure 1. Study flow chart of patient identification and selectionStudy flow chart of patient identification and selection. A total of 117 records were excluded from the 3431 cases registered in the coronavirus disease 2019 (COVID-19) taskforce database owing to lack of essential clinical information. Ultimately, 3314 patients met the eligibility criteria, of which 2709 had respiratory symptoms. Supplemental Figure 2. Frequency of assisted respiration therapy and death in all four groups (a) Univariate analysis of the proportion of high-flow oxygen therapy with COVID-19 in each group. (b) Univariate analysis of the proportion of use of invasive mechanical ventilation (IMV) with COVID-19 in each group. (c) Univariate analysis of the proportion of use of extracorporeal membrane oxygenation (ECMO) with COVID-19 in each group. (d) Univariate analysis of the proportion of death with COVID-19 in each group. Supplemental Table 1. Common non-respiratory symptoms in each group
Additional file 6 of Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study
Additional file 6. Admission to intensive care unitand use of invasive mechanical ventilationof bacterial respiratory infection with coronavirus disease 2019
Additional file 4 of Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study
Additional file 4. Details of respiratory secondary infection
Additional file 8 of Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study
Additional file 8. Proportion of thrombosis and myocardial injury in bacterial respiratory co-infection and secondary infection with coronavirus disease 2019
Additional file 5 of Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study
Additional file 5. Association of anti-IL-6 receptor antibody use with incidence of secondary infection and death
Additional file 1 of Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study
Additional file 1. Identification of organisms in ventilator-associated pneumoniacase